JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

32 -4.31

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.6

Max

33.07

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+68.15% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.6B
Ankstesnė atidarymo kaina	36.31
Ankstesnė uždarymo kaina	32

Naujienos nuotaikos

By Acuity

50%

177 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-28 23:33; UTC

Karštos akcijos

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

2026-04-28 23:24; UTC

Uždarbis

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

2026-04-28 23:15; UTC

Svarbiausios naujienos

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

2026-04-28 22:46; UTC

Uždarbis

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

2026-04-28 22:37; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

2026-04-28 22:15; UTC

Uždarbis

Svarbiausios naujienos

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

2026-04-28 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

2026-04-28 23:31; UTC

Uždarbis

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

2026-04-28 23:31; UTC

Uždarbis

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

2026-04-28 23:30; UTC

Uždarbis

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

2026-04-28 23:30; UTC

Uždarbis

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

2026-04-28 23:19; UTC

Rinkos pokalbiai

Uždarbis

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

2026-04-28 23:09; UTC

Uždarbis

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

2026-04-28 23:03; UTC

Rinkos pokalbiai

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees One Rate Rise to 4% in Benign Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

2026-04-28 22:51; UTC

Uždarbis

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

2026-04-28 22:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-28 22:48; UTC

Rinkos pokalbiai

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

2026-04-28 22:40; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

2026-04-28 22:32; UTC

Uždarbis

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

2026-04-28 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Pernod Ricard and Brown-Forman End Deal Talks -- Update

2026-04-28 22:22; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

2026-04-28 22:17; UTC

Rinkos pokalbiai

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

2026-04-28 22:14; UTC

Uždarbis

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

2026-04-28 22:14; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

2026-04-28 22:07; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

68.15% į viršų

12 mėnesių prognozė

Vidutinis 56.6 USD 68.15%

Aukščiausias 90 USD

Žemiausias 34 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

177 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.